Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

China Health Industries Holdings, Inc. (CHHE) EBITDA Margin (2017 - 2024)

China Health Industries Holdings (CHHE) has disclosed EBITDA Margin for 13 consecutive years, with 123997.7% as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, EBITDA Margin fell 12347286.0% year-over-year to 123997.7%, compared with a TTM value of 3732.39% through Mar 2024, down 30208.0%, and an annual FY2023 reading of 3309.9%, up 73523767.0% over the prior year.
  • EBITDA Margin was 123997.7% for Q1 2024 at China Health Industries Holdings, up from 526956.52% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 96348350.0% in Q2 2022 and bottomed at 4144900.0% in Q1 2022.
  • Average EBITDA Margin over 5 years is 5166171.82%, with a median of 12.95% recorded in 2021.
  • The sharpest move saw EBITDA Margin soared 2000000000bps in 2022, then tumbled 2000000000bps in 2023.
  • Year by year, EBITDA Margin stood at 82.64% in 2020, then plummeted by -4535383bps to 3748050.0% in 2021, then soared by 100bps to 8430.16% in 2022, then tumbled by -6351bps to 526956.52% in 2023, then surged by 76bps to 123997.7% in 2024.
  • Business Quant data shows EBITDA Margin for CHHE at 123997.7% in Q1 2024, 526956.52% in Q4 2023, and 1100.76% in Q3 2023.